{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:52Z","timestamp":1783930372506,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04113-8","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:22:12Z","timestamp":1782098532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of Pemafibrate on glucose metabolism and FGF21: a systematic review and meta-analysisa of randomized controlled trials"],"prefix":"10.1007","volume":"82","author":[{"given":"Haiyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Sohouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"9","key":"4113_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S2213-8587(24)00127-X","volume":"12","author":"M Abdul-Ghani","year":"2024","unstructured":"Abdul-Ghani M, Maffei P, DeFronzo RA (2024) Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes. Lancet Diabetes Endocrinol 12(9):674\u2013680","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"4113_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B (2021) PPAR control of metabolism and cardiovascular functions. Nat Reviews Cardiol 18(12):809\u2013823","journal-title":"Nat Reviews Cardiol"},{"issue":"3","key":"4113_CR3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1038\/sj.ijo.0802494","volume":"27","author":"D Moller","year":"2003","unstructured":"Moller D, Berger J (2003) Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes 27(3):S17\u2013S21","journal-title":"Int J Obes"},{"issue":"11","key":"4113_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/biom14111445","volume":"14","author":"M Ma\u0142odobra-Mazur","year":"2024","unstructured":"Ma\u0142odobra-Mazur M, O\u0142dakowska M, Dobosz T (2024) Exploring PPAR Gamma and PPAR Alpha\u2019s Regulation Role in Metabolism via Epigenetics Mechanism. Biomolecules 14(11):1445","journal-title":"Biomolecules"},{"issue":"6","key":"4113_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00380-024-02363-z","volume":"39","author":"A Nakamura","year":"2024","unstructured":"Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H (2024) Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome. Heart Vessels 39(6):486\u2013495","journal-title":"Heart Vessels"},{"issue":"9","key":"4113_CR6","doi-asserted-by":"publisher","first-page":"e70277","DOI":"10.1002\/jgh3.70277","volume":"9","author":"Y Komiyama","year":"2025","unstructured":"Komiyama Y, Tamaki N, Tsuji K, Mori N, Mashiba T, Ochi H, Kobashi H, Ogawa C, Nonogi M, Yoshida H et al (2025) Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study. JGH Open 9(9):e70277","journal-title":"JGH Open"},{"issue":"21","key":"4113_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ et al (2022) Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 387(21):1923\u20131934","journal-title":"N Engl J Med"},{"issue":"5","key":"4113_CR8","doi-asserted-by":"publisher","first-page":"E409","DOI":"10.1152\/ajpendo.00244.2022","volume":"324","author":"A Velingkar","year":"2023","unstructured":"Velingkar A, Vuree S, Prabhakar PK, Kalashikam RR, Banerjee A, Kondeti S (2023) Fibroblast growth factor 21 as a potential master regulator in metabolic disorders. Am J Physiology-Endocrinology Metabolism 324(5):E409\u2013E424","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"key":"4113_CR9","doi-asserted-by":"publisher","first-page":"1496671","DOI":"10.3389\/fendo.2025.1496671","volume":"16","author":"T Suzuki","year":"2025","unstructured":"Suzuki T, Sato T, Tanaka M, Nakata K, Endo K, Aida H, Kawaharata W, Hosaka I, Umetsu A, Ogawa T (2025) Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus. Front Endocrinol 16:1496671","journal-title":"Front Endocrinol"},{"issue":"7","key":"4113_CR10","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/pharmaceutics15071838","volume":"15","author":"H Nomoto","year":"2023","unstructured":"Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY (2023) Favorable effect of pemafibrate on insulin resistance and \u03b2-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study. Pharmaceutics 15(7):1838","journal-title":"Pharmaceutics"},{"issue":"6","key":"4113_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/jdi.12845","volume":"9","author":"I Matsuba","year":"2018","unstructured":"Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E (2018) Effects of a novel selective peroxisome proliferator-activated receptor\u2010\u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Invest 9(6):1323\u20131332","journal-title":"J Diabetes Invest"},{"key":"4113_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart J-C, Kodama T (2016) Group K\u2013S: Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active-and placebo-controlled, phase 2 trial. Atherosclerosis 249:36\u201343","journal-title":"Atherosclerosis"},{"issue":"1","key":"4113_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S (2021) Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo\u2010controlled clinical trials. Cardiovasc Diabetol 20(1):96","journal-title":"Cardiovasc Diabetol"},{"key":"4113_CR14","doi-asserted-by":"crossref","unstructured":"Booth A, Mitchell AS, Mott A, James S, Cockayne S, Gascoyne S, McDaid C (2020) An assessment of the extent to which the contents of PROSPERO records meet the systematic review protocol reporting items in PRISMA-P. F1000Research 9","DOI":"10.12688\/f1000research.25181.2"},{"key":"4113_CR15","doi-asserted-by":"crossref","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA (2019) Assessing risk of bias in a randomized trial. Cochrane Handb Syst reviews interventions 205\u2013228","DOI":"10.1002\/9781119536604.ch8"},{"issue":"6","key":"4113_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3945\/an.116.013052","volume":"7","author":"L Schwingshackl","year":"2016","unstructured":"Schwingshackl L, Kn\u00fcppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, Dietrich S, Eichelmann F, Kontopantelis E, Iqbal K et al (2016) Perspective: NutriGrade: A Scoring System to Assess and Judge the Meta-Evidence of Randomized Controlled Trials and Cohort Studies in Nutrition Research. Adv Nutr 7(6):994\u20131004","journal-title":"Adv Nutr"},{"key":"4113_CR17","unstructured":"Higgins J (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org"},{"issue":"1","key":"4113_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"4113_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"7109","key":"4113_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"3","key":"4113_CR21","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y (2018) Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41(3):538\u2013546","journal-title":"Diabetes Care"},{"issue":"Supplement1","key":"4113_CR22","first-page":"S339","volume":"49","author":"16","year":"2026","unstructured":"16 (2026) Diabetes Care in the Hospital: Standards of Care in Diabetes\u20142026. Diabetes Care 49(Supplement1):S339\u2013S355","journal-title":"Diabetes Care"},{"issue":"5","key":"4113_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.14740\/jem765","volume":"11","author":"DA-W Mohamed","year":"2021","unstructured":"Mohamed DA-W, Elayat WM, Abozeid AA, Abdel-Salam MF, Teama NM, Abdelrahim DS, Tamim YM (2021) Glucose transporter 4 and peroxisome proliferator-activated receptor-alpha overexpression association with cardioprotective effects of myoinositol and metformin combination in type 2 diabetic rat model. J Endocrinol Metabolism 11(5):140\u2013151","journal-title":"J Endocrinol Metabolism"},{"issue":"3","key":"4113_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4093\/dmj.2023.0370","volume":"48","author":"R Izumihara","year":"2024","unstructured":"Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY (2024) Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease. Diabetes Metabolism J 48(3):473\u2013481","journal-title":"Diabetes Metabolism J"},{"issue":"6","key":"4113_CR25","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al (2005) FGF-21 as a novel metabolic regulator. J Clin Investig 115(6):1627\u20131635","journal-title":"J Clin Investig"},{"issue":"6","key":"4113_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabol 5(6):415\u2013425","journal-title":"Cell Metabol"},{"issue":"1","key":"4113_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"J-C Fruchart","year":"2017","unstructured":"Fruchart J-C (2017) Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16(1):124","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"4113_CR28","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19):2088\u20132093","journal-title":"Circulation"},{"key":"4113_CR29","doi-asserted-by":"crossref","unstructured":"Murakami K, Sasaki Y, Asahiyama M, Yano W, Takizawa T, Kamiya W, Matsumura Y, Anai M, Osawa T, Fruchart JC et al (2022) Selective PPAR\u03b1 modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis. Cells 11(4):720","DOI":"10.3390\/cells11040720"},{"issue":"1","key":"4113_CR30","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","volume":"10","author":"Y Sasaki","year":"2020","unstructured":"Sasaki Y, Asahiyama M, Tanaka T, Yamamoto S, Murakami K, Kamiya W, Matsumura Y, Osawa T, Anai M, Fruchart JC et al (2020) Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci Rep 10(1):7818","journal-title":"Sci Rep"},{"issue":"8","key":"4113_CR31","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc08-0545","volume":"31","author":"DM Nathan","year":"2008","unstructured":"Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31(8):1473\u20131478","journal-title":"Diabetes Care"},{"issue":"32","key":"4113_CR32","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38(32):2459\u20132472","journal-title":"Eur Heart J"},{"issue":"10","key":"4113_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jgh3.12650","volume":"5","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Kosone T, Saito N, Takakusagi S, Tojima H, Naganuma A, Takagi H, Uraoka T, Kakizaki S (2021) Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 5(10):1183\u20131189","journal-title":"JGH Open"},{"issue":"3","key":"4113_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5114\/ceh.2020.99528","volume":"6","author":"S Shinozaki","year":"2020","unstructured":"Shinozaki S, Tahara T, Lefor AK, Ogura M (2020) Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin experimental Hepatol 6(3):270\u2013274","journal-title":"Clin experimental Hepatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04113-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:37Z","timestamp":1783929457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04113-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}